{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:08:47Z","timestamp":1791198527944,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T00:00:00Z","timestamp":1269475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:p><jats:bold>Background and purpose:\u2002<\/jats:bold>The therapeutic potential of cannabinoids in Huntington's disease (HD) has been investigated by several groups with complex and sometimes contrasting results. We sought to examine key points of intersection between cannabinoid receptor 1 (CB<jats:sub>1<\/jats:sub>) signalling, survival and the formation of mutant huntingtin aggregates in HD.<\/jats:p><jats:p><jats:bold>Experimental approach:\u2002<\/jats:bold>Using a simplified pheochromocytoma (PC12) cell model of HD expressing exon 1 of wild\u2010type or mutant huntingtin, we assayed cell death and aggregate formation using high\u2010throughput cytotoxicity and image\u2010based assays respectively.<\/jats:p><jats:p><jats:bold>Key results:\u2002<\/jats:bold>CB<jats:sub>1<\/jats:sub>activation by HU210 conferred a small but significant level of protection against mutant huntingtin\u2010induced cell death.<jats:italic>Pertussis<\/jats:italic>toxin uncoupled HU210 from the inhibition of cAMP, preventing rescue of cell death. Phosphorylation of extracellular signal\u2010regulated kinase (ERK) was also critical to CB<jats:sub>1<\/jats:sub>\u2010mediated rescue. Conversely, treatments that elevated cAMP exacerbated mutant huntingtin\u2010induced cell death. Despite opposing effects on HD cell survival, both HU210 and compounds that elevated cAMP increased the formation of mutant huntingtin aggregates. The increase in aggregation by HU210 was insensitive to<jats:italic>Pertussis<\/jats:italic>toxin and UO126, suggesting a G\u2010protein alpha subtype s (G<jats:sub>s<\/jats:sub>)\u2010linked mechanism.<\/jats:p><jats:p><jats:bold>Conclusions and implications:\u2002<\/jats:bold>We suggest that the CB<jats:sub>1<\/jats:sub>receptor, through G\u2010protein alpha subtype i\/o (G<jats:sub>i\/o<\/jats:sub>)\u2010linked, ERK\u2010dependent signal transduction, is a therapeutic target in HD. However the protective potential of CB<jats:sub>1<\/jats:sub>may be limited by promiscuous coupling to G<jats:sub>s<\/jats:sub>, the stimulation of cAMP formation and increased aggregate formation. This may underpin the poor therapeutic efficacy of cannabinoids in more complex model systems and suggest that therapies that are selective for the G<jats:sub>i\/o<\/jats:sub>, ERK pathway may be of most benefit in HD.<\/jats:p><jats:p>This article is part of a themed issue on Cannabinoids. To view the editorial for this themed issue visit<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/dx.doi.org\/10.1111\/j.1476-5381.2010.00831.x\">http:\/\/dx.doi.org\/10.1111\/j.1476\u20105381.2010.00831.x<\/jats:ext-link><\/jats:p>","DOI":"10.1111\/j.1476-5381.2010.00773.x","type":"journal-article","created":{"date-parts":[[2010,3,26]],"date-time":"2010-03-26T02:32:41Z","timestamp":1269570761000},"page":"747-761","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Neuroprotective potential of CB<sub>1<\/sub>receptor agonists in an<i>in vitro<\/i>model of Huntington's disease"],"prefix":"10.1111","volume":"160","author":[{"given":"EL","family":"Scotter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CE","family":"Goodfellow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ES","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Dragunow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,5,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2004.04.001"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/sj.bjp.0707746","article-title":"Guide to Receptors and Channels (GRAC), 3rd edition","volume":"153","author":"Alexander SP","year":"2008","journal-title":"Br J Pharmacol"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1289-05.2005"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1006\/nimg.2001.0939"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0022-3565(24)37876-0","article-title":"Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist\u2010specific trafficking of intracellular responses","volume":"287","author":"Bonhaus DW","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.26.010302.081142"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2006.07.008"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0502698102"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.2001.4850"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3495(03)74856-5"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.062836"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/35008142"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.02505"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2931802"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.17-14-05327.1997"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.56.6.1362"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(96)00428-9"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(00)00008-7"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(03)00595-5"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-2333(01)00014-5"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M602516200"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3155875"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.2008.04991.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1995.64020677.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2005.03348.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0065-2571(94)00012-R"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0026-895X(25)10219-8","article-title":"Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs","volume":"29","author":"Howlett AC","year":"1986","journal-title":"Mol Pharmacol"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506375102"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.20.11404"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.006882"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-5822.2007.00901.x"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2005.06.001"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.11.6448"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200305060-00007"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2003.01595.x"},{"key":"e_1_2_8_37_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.31887\/dcns.2001.3.1\/hlehrach","article-title":"Huntington's disease: from gene to potential therapy","volume":"3","author":"Lehrach H","year":"2001","journal-title":"Dialogues Clin Neurosci"},{"key":"e_1_2_8_38_1","unstructured":"RasbandWS(19972009).ImageJ 1.34s edn. Bethesda Maryland USA: U. S. National Institutes of Health [WWW document]. URLhttp:\/\/rsb.info.nih.gov\/ij\/."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2008.02.052"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1566-2772(00)00014-1"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706661"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01301"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.8.4604"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2008.02.007"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1658-03.2004"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/35099568"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.14.7999"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4889(85)90159-4"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(95)12025-Y"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929866043407174"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(02)00733-X"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.2010.00773.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2010.00773.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T18:25:58Z","timestamp":1739989558000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.2010.00773.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,19]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1111\/j.1476-5381.2010.00773.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00773.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,19]]},"assertion":[{"value":"2010-05-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}